UK – NICE nod for Jazz’ AML chemo

Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).

In a Final Appraisal Determination the Institute has approved funding for the drug when used to treat adults with newly diagnosed, therapy-related t-AML or AML with myelodysplasia-related changes (AML-MRC), two types of secondary AML.

“This is the first new chemotherapy in forty years for adults with specific types of newly diagnosed secondary AML, a particularly aggressive cancer that typically affects older people and has a high mortality rate,” said Dr Nigel Russell, Professor of Haematology, Faculty of Medicine & Health Sciences at the University of Nottingham…